ACRO BIOMEDICAL CO., LTD.

$ Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000164033421000767 Filed on April 02, 2021

Income Statement

Concept	2020	2019 Q4	2019 Q3

Balance Sheet

Concept	2020	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.12K	$910.00	$1.470K
YoY Change	1891.21%	-97.58%	27.83%
Cash & Equivalents	$18.12K	$911.00	$1.472K
Short-Term Investments
Other Short-Term Assets	$17.23K	$0.00	$7.990K
YoY Change		-100.0%	-97.58%
Inventory	$938.0K	$878.6K	$1.060M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$973.4K	$879.5K	$1.069M
YoY Change	10.67%	-29.7%	-27.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.70K	$48.43K
YoY Change	-49.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$4.230K	$0.00
YoY Change		-78.79%	-100.0%
Total Long-Term Assets	$24.70K	$52.66K	$0.00
YoY Change	-53.1%	163.93%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$973.4K	$879.5K	$1.069M
Total Long-Term Assets	$24.70K	$52.66K	$0.00
Total Assets	$998.1K	$932.1K	$1.069M
YoY Change	7.07%	-26.66%	-27.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.73K	$23.83K	$18.02K
YoY Change	3.78%	214.38%	146.51%
Accrued Expenses	$24.50K	$23.96K
YoY Change	2.25%
Deferred Revenue
YoY Change
Short-Term Debt	$243.0K	$26.28K	$61.77K
YoY Change	824.47%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$312.2K	$111.5K	$195.8K
YoY Change	179.89%	8.21%	-18.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$22.35K
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$22.35K	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$312.2K	$111.5K	$195.8K
Total Long-Term Liabilities	$0.00	$22.35K	$0.00
Total Liabilities	$312.2K	$133.9K	$195.8K
YoY Change	133.17%	29.89%	-18.65%
SHAREHOLDERS EQUITY
Retained Earnings		-$121.2K
YoY Change
Common Stock		$919.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$685.9K	$798.2K	$873.7K
YoY Change
Total Liabilities & Shareholders Equity	$998.1K	$932.1K	$1.069M
YoY Change	7.07%	-26.66%	-27.88%

Cashflow Statement

Concept	2020	2019 Q4	2019 Q3

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020Q2	dei	Entity Public Float EntityPublicFloat	44400000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18123	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	911	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37607	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1472	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1148	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	938000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	878560	USD
CY2020Q4	acbm	Purchase Deposit For Inventory PurchaseDepositForInventory	12000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1000	USD
CY2020Q4	acbm	Security Deposit Current SecurityDepositCurrent	4230	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	973353	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	879471	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24700	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48425	USD
CY2019Q4	us-gaap	Security Deposit SecurityDeposit	4230	USD
CY2020Q4	us-gaap	Assets Assets	998053	USD
CY2019Q4	us-gaap	Assets Assets	932126	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24734	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23834	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	USD
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	37464	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	242951	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	26279	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24500	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	23964	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	312185	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	111541	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22346	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	312185	USD
CY2019Q4	us-gaap	Liabilities Liabilities	133887	USD
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47760000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47760000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47760000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47760000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	47760	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	47760	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	876762	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	871680	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238654	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121201	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	685868	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798239	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1167860	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	1242154	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	873672	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	998053	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	932126	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	687964	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	193536	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	193536	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1354000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	528560	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	181440	USD
CY2019Q4	us-gaap	Cost Of Revenue CostOfRevenue	181440	USD
CY2018Q4	us-gaap	Cost Of Revenue CostOfRevenue	1218600	USD
CY2020	us-gaap	Gross Profit GrossProfit	159404	USD
CY2019	us-gaap	Gross Profit GrossProfit	12096	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	12096	USD
CY2018Q4	us-gaap	Gross Profit GrossProfit	135400	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289867	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	434847	USD
CY2019Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	87529	USD
CY2018Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	229635	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	289867	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	434847	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	87529	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-75016	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	229635	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-130463	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-422751	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-75433	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-94235	USD
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5082	USD
CY2019	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1983	USD
CY2019Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	440	USD
CY2018Q4	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	722	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5082	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1983	USD
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-440	USD
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-722	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-135545	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-424734	USD
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-75873	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-94957	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18092	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53130	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19941	USD
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117453	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-371604	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-75873	USD
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47760000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47760000	shares
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47760000	shares
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47760000	shares
CY2019	acbm	Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans	1983	USD
CY2020	acbm	Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans	5082	USD
CY2018Q4	acbm	Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans	722	USD
CY2019Q4	acbm	Adjustments To Additional Paid In Capital Imputed Interest On Related Party Loans AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyLoans	440	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	148395	USD
CY2018Q4	us-gaap	Share Based Compensation ShareBasedCompensation	151694	USD
CY2020	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	-5082	USD
CY2019	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	-1983	USD
CY2019Q4	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	-440	USD
CY2018Q4	acbm	Imputed Interest Related Parties ImputedInterestRelatedParties	-722	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-19941	USD
CY2018Q4	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	19941	USD
CY2020	acbm	Increase Decrease In Right Of Use Asset And Lease Liability IncreaseDecreaseInRightOfUseAssetAndLeaseLiability	1915	USD
CY2019	acbm	Increase Decrease In Right Of Use Asset And Lease Liability IncreaseDecreaseInRightOfUseAssetAndLeaseLiability	-2115	USD
CY2018Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	270	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-19156	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17464	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37464	USD
CY2019Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-78536	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-199460	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59709	USD
CY2019Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34928	USD
CY2018Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	174329	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	216672	USD
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	118014	USD
CY2019Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	14511	USD
CY2018Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3466	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	95001	USD
CY2019Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	50000	USD
CY2019	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-73071	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	59440	USD
CY2018Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	141336	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216672	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23013	USD
CY2019Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-35489	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-181440	USD
CY2019Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-181440	USD
CY2018Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-86600	USD
CY2020	acbm	Increase Decrease In Purchase Deposit For Inventory IncreaseDecreaseInPurchaseDepositForInventory	12000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1000	USD
CY2019Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-885	USD
CY2018Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-30000	USD
CY2019	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	762	USD
CY2019Q4	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	762	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	900	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16252	USD
CY2019Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5810	USD
CY2018Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-137870	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17212	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-36696	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-561	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	36459	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	19156	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q4	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018Q4	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q4	acbm	Increase In Right Of Use Asset And Lease Liability IncreaseInRightOfUseAssetAndLeaseLiability	46310	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt"><strong><em>Use of Estimates</em></strong></span></p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"> </p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">The preparation of financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> </div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt"><strong><em>Concentrations of Credit Risk</em></strong></span></p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"> </p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables that it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high creditworthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits.</span></p> </div>
CY2020	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt"><strong><em>Deferred Revenue</em></strong></span></p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"> </p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify">The Company sells products pursuant to agreements for the delivery of products to customers. The Company receives cash in advance and records it as deferred revenue.</p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px;text-align:justify"> </p> <p style="FONT-SIZE:10pt;FONT-FAMILY:times new roman;MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">Deferred revenue at December 31, 2020 and 2019, was $20,000 and $37,464, respectively.</span></p> </div>
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28464	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-89194	USD
CY2019Q4	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15933	USD
CY2018Q4	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19941	USD
CY2020	acbm	Expense Not Deductible In Current Period ExpenseNotDeductibleInCurrentPeriod	0	USD
CY2019	acbm	Expense Not Deductible In Current Period ExpenseNotDeductibleInCurrentPeriod	69319	USD
CY2019Q4	acbm	Expense Not Deductible In Current Period ExpenseNotDeductibleInCurrentPeriod	0	USD
CY2018Q4	acbm	Expense Not Deductible In Current Period ExpenseNotDeductibleInCurrentPeriod	0	USD
CY2020	acbm	Imputed Interest ImputedInterest	1067	USD
CY2019	acbm	Imputed Interest ImputedInterest	568	USD
CY2019Q4	acbm	Imputed Interest ImputedInterest	92	USD
CY2018Q4	acbm	Imputed Interest ImputedInterest	0	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-18092	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-73071	USD
CY2019Q4	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	0	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	0	USD
CY2020	acbm	Operating Losses Utilized OperatingLossesUtilized	27397	USD
CY2019	acbm	Operating Losses Utilized OperatingLossesUtilized	39248	USD
CY2019Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	7560	USD
CY2018Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8560	USD
CY2019Q4	acbm	Operating Losses Utilized OperatingLossesUtilized	15841	USD
CY2018Q4	acbm	Operating Losses Utilized OperatingLossesUtilized	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66645	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39248	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66645	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39248	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	317000	USD
CY2020	acbm	Imputed Interest Rate ImputedInterestRate	0.04	pure
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24500	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	46310	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	24941	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	24941	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	26141	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	31240	USD

Files In Submission

Name	View Source	Status
0001640334-21-000767-index-headers.html	Edgar Link	pending
0001640334-21-000767-index.html	Edgar Link	pending
0001640334-21-000767.txt	Edgar Link	pending
0001640334-21-000767-xbrl.zip	Edgar Link	pending
acbm-20201231.xml	Edgar Link	completed
acbm-20201231.xsd	Edgar Link	pending
acbm-20201231_cal.xml	Edgar Link	unprocessable
acbm-20201231_def.xml	Edgar Link	unprocessable
acbm-20201231_lab.xml	Edgar Link	unprocessable
acbm-20201231_pre.xml	Edgar Link	unprocessable
acro_10k.htm	Edgar Link	pending
acro_ex311.htm	Edgar Link	pending
acro_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

ACRO BIOMEDICAL CO., LTD.

2020 Form 10-K Financial Statement

#000164033421000767 Filed on April 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission